A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Clinical trial NCT03403712 · COMPLETED
Trial details
- NCT number
- NCT03403712
- Sponsor
- Helsinn Healthcare SA
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-16
- Primary completion
- 2018-09-19
- Enrollment
- 404
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.